Tagworks Pharmaceuticals raises €60 million to proceed towards clinical trials
Tagworks Pharmaceuticals started as a spin-off from Philips Research and has now successfully completed a major investment round. The financial boost provides the resources to initiate clinical trials with the company’s lead candidate ADC which targets solid tumors.
Want to read more?
Create a free account today!
- Gain access to all our content on chemistry, life sciences and process technology;
- Get our weekly newsletter so you never miss a story.
As a member of the KNCV, KVCV, NBV, or NVBMB you have unlimited access. Log in here.
